Zevra Therapeutics (ZVRA) Interest & Investment Income (2014 - 2026)

Zevra Therapeutics (ZVRA) has 13 years of Interest & Investment Income data on file, last reported at $3.6 million in Q1 2026.

• Quarterly Interest & Investment Income rose 560.96% year-over-year to $3.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.0 million (up 458.52% YoY) and the FY2025 annual result came in at $6.9 million, up 219.36% from the prior year.
• Interest & Investment Income rose to $3.6 million in Q1 2026, from $1.7 million in the prior quarter.
• In the past five years, Interest & Investment Income ranged from a high of $3.6 million in Q1 2026 to a low of -$73000.0 in Q4 2024.
• A 5-year average of $1.1 million and a median of $1.0 million in 2022 frame the typical range for Interest & Investment Income.
• Annual changes were most pronounced in 2022 — Interest & Investment Income jumped 8466.67% — and 2024, when it slumped 134.76%.
• Tracing ZVRA's Interest & Investment Income over 5 years: stood at $1.0 million in 2022, then sank by 79.63% to $210000.0 in 2023, then tumbled by 134.76% to -$73000.0 in 2024, then jumped by 2445.21% to $1.7 million in 2025, then jumped by 109.64% to $3.6 million in 2026.
• The last three Interest & Investment Income figures came in at $3.6 million (Q1 2026), $1.7 million (Q4 2025), and $2.3 million (Q3 2025), per Business Quant data.